Compare GSUN & SNOA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GSUN | SNOA |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 4.0M |
| IPO Year | 2020 | 2006 |
| Metric | GSUN | SNOA |
|---|---|---|
| Price | $0.41 | $1.26 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 2.5M | 87.8K |
| Earning Date | 02-13-2026 | 06-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 32.26 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,529,000.00 |
| Revenue This Year | N/A | $23.00 |
| Revenue Next Year | N/A | $24.59 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 36.68 |
| 52 Week Low | $0.29 | $0.85 |
| 52 Week High | $3.31 | $6.92 |
| Indicator | GSUN | SNOA |
|---|---|---|
| Relative Strength Index (RSI) | 49.12 | 58.15 |
| Support Level | $0.35 | $1.02 |
| Resistance Level | $0.55 | $3.92 |
| Average True Range (ATR) | 0.06 | 0.06 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 47.48 | 76.19 |
Golden Sun Technology Group Ltd operates two principal lines of business: tutorial services and e-commerce services. The company's e-commerce operations currently consist of data analytics-driven marketing and social media promotional services for small and medium-sized businesses on short video platforms based in China. The company's education centers offer two main programs, comprising of foreign language tutorial programs in less commonly taught languages, including, among other things, Spanish and Japanese, provided to individual students as well as to companies and other organizations; and Gaokao repeater tutorial programs, provided to individual students.
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.